- Home
- GLSI vs IPHA Comparison
GLSI vs IPHA Comparison
Compare GLSI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- IPHA
- Stock Information
- Founded
- GLSI 2006
- IPHA 1999
- Country
- GLSI United States
- IPHA France
- Employees
- GLSI N/A
- IPHA N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- GLSI Health Care
- IPHA Health Care
- Exchange
- GLSI Nasdaq
- IPHA Nasdaq
- Market Cap
- GLSI 133.4M
- IPHA 160.1M
- IPO Year
- GLSI 2020
- IPHA 2019
- Fundamental
- Price
- GLSI $9.66
- IPHA $2.17
- Analyst Decision
- GLSI Strong Buy
- IPHA Strong Buy
- Analyst Count
- GLSI 1
- IPHA 1
- Target Price
- GLSI $39.00
- IPHA $11.00
- AVG Volume (30 Days)
- GLSI 36.1K
- IPHA 16.2K
- Earning Date
- GLSI 05-20-2025
- IPHA 03-27-2025
- Dividend Yield
- GLSI N/A
- IPHA N/A
- EPS Growth
- GLSI N/A
- IPHA N/A
- EPS
- GLSI N/A
- IPHA N/A
- Revenue
- GLSI N/A
- IPHA $20,831,349.00
- Revenue This Year
- GLSI N/A
- IPHA $209.83
- Revenue Next Year
- GLSI N/A
- IPHA $83.15
- P/E Ratio
- GLSI N/A
- IPHA N/A
- Revenue Growth
- GLSI N/A
- IPHA N/A
- 52 Week Low
- GLSI $8.06
- IPHA $1.29
- 52 Week High
- GLSI $18.75
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- GLSI 48.32
- IPHA 52.87
- Support Level
- GLSI $9.25
- IPHA $2.02
- Resistance Level
- GLSI $10.00
- IPHA $2.21
- Average True Range (ATR)
- GLSI 0.48
- IPHA 0.08
- MACD
- GLSI -0.02
- IPHA -0.01
- Stochastic Oscillator
- GLSI 30.10
- IPHA 68.18
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.